Effect of Herbal Extracts on Antituberculosis Drug‐Induced Hepatotoxicity: A Systematic Review Surthi M Ravedar, Kranthi Kiran Akula, Kalesh M Karun, Flemin Felix, Kamran Zaman, Jyothi Bhat, Subarna Roy, Lissinda H Du Plessis Abstract AbstractBackgroundTuberculosis (TB) remains a major global health challenge. While effective, first‐line antitubercular drugs such as isoniazid and rifampicin often cause hepatotoxicity, limiting treatment safety. Herbal extracts with antioxidant and hepatoprotective properties may help mitigate this liver damage. This systematic review evaluates the protective effects of plant extracts against antitubercular drug‐induced hepatotoxicity, aiming to inform potential adjuvant strategies.MethodsFollowing PRISMA‐P guidelines, PubMed, Scopus, and Google Scholar were searched for “in vivo studies assessing plant extracts against hepatotoxicity caused by anti‐TB drugs.” Two independent reviewers screened and extracted data. Study quality was evaluated using SYRCLE’s risk of bias tool.ResultsSixty‐eight in vivo studies were included. Overall, plant extracts demonstrated variable hepatoprotective efficacy, with some showing significant improvement in certain species—Luffa acutangula L., Lawsonia inermis L., and Cucumis trigonus Roxb. showed the highest reduction in serum liver enzymes: aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) in U/L, and total bilirubin (TBil) and antioxidant parameters glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD), suggesting hepatoprotective potential.ConclusionMedicinal plants demonstrate variable hepatoprotective effects in animal models of anti‐TB drug‐induced liver injury, though their mechanisms of oxidative stress remain unclear. Among them, the extracts from Luffa acutangula L., Lawsonia inermis L., and Cucumis trigonus Roxb. showed promising hepatoprotective effects. These effects are likely associated with antioxidant and cytoprotective mechanisms. However, further well‐designed preclinical and clinical research are required to establish their dosage, safety, and efficacy before integration into TB therapy. Trial Registration: PROSPERO: CRD42024563060.Keywords: anti-TB drugs, drug-induced liver injury, drug toxicity, hepatoprotective, hepatotoxicity, herbal extract, plant extract, tuberculosis 1. Introduction Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), remains a major public health concern and one of the leading causes of infectious disease‐related mortality worldwide. Despite the availability of vaccines and effective antitubercular drugs and treatment, 10.6 million new TB cases and 1.5 million deaths are reported annually [, ]. The standard directly observed treatment short‐course (DOTS) protocol—comprising isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB)—is highly effective in controlling TB; however, its clinical utility is frequently limited by adverse reactions, particularly antitubercular drug–induced hepatotoxicity []. The liver is a multifunctional organ controlling vital processes involving metabolism, detoxification, and nutrient regulation []. As the primary organ of drug metabolism, the liver is highly susceptible to damage from pharmaceutical compounds due to the nonspecific activity of its versatile enzymes, often leading to drug‐induced hepatotoxicity []. Drug‐induced hepatotoxicity is a key problem that limits therapy and medication usage. More than 900 medications, such as acetaminophen, chloroquine, and INH, can cause hepatotoxicity. First‐line antitubercular medicines cause hepatotoxicity predominantly through the formation of reactive metabolites via oxidative stress, mitochondrial dysfunction, and immune‐mediated pathways. N‐acetyltransferase 2 (NAT2) metabolizes INH in the liver to acetyl hydrazine and hydrazine, which undergo oxidation by cytochrome P450 2E1 (CYP2E1) into hepatotoxic intermediates that generate reactive oxygen species (ROS), resulting in lipid peroxidation, mitochondrial damage, and hepatocyte apoptosis or necrosis. RIF exacerbates INH‐induced hepatotoxicity by inducing hepatic CYP enzymes (particularly CYP3A4 and CYP2E1), thereby increasing the toxic metabolites. RIF also disrupts bile acid homeostasis via pregnane X receptor (PXR)‐mediated regulation, contributing to cholestatic liver injury. PZA gets converted to pyrazinoic acid and 5‐hydroxy‐pyrazinoic acid, which cause direct dose‐dependent hepatocellular damage, including hepatic inflammation, mitochondrial dysfunction, and necrosis. EMB has a low intrinsic hepatotoxic potential. It is infrequently associated with liver injury, with most clinical evidence indicating a minor role in hepatotoxicity when compared to INH, RIF, and PZA. These drugs cause liver injury through a combination of mechanisms, including oxidative stress, activation of metabolic enzymes, inflammatory signaling, and altered hepatic detoxification pathways. Recent investigations have shown a strong link between hepatic damage and oxidative stress in experimental animals treated with antituberculosis drugs [, ]. Conventional management of antituberculosis drug-induced hepatotoxicity (ATDH) includes temporary withdrawal and/or substitution of offending drugs, along with the use of hepatoprotective agents to mitigate liver injury. Among these, silymarin, a flavonolignan complex extracted from Silybum marianum (milk thistle), has been extensively studied for its hepatoprotective, antioxidant, and membrane‐stabilizing properties. It scavenges free radicals and enhances hepatic glutathione (GSH) levels, thereby protecting hepatocytes from damage caused by drugs such as INH and RIF. A randomized controlled trial demonstrated that silymarin significantly reduced the incidence of ATDH in patients undergoing anti‐TB therapy []. Another widely used formulation is “Liv.52,” a proprietary polyherbal product developed by the Himalaya Drug Company. It contains Mandur Bhasma and extracts of Capparis spinosa, Cichorium intybus, and Solanum nigrum, among others. Liv.52 has been shown to normalize hepatic enzyme levels and reduce oxidative stress, thereby supporting liver function. A clinical study confirmed its hepatoprotective effects in TB patients, significantly reducing the levels of serum transaminase and improving liver function markers []. Plant‐derived formulations are increasingly used as supportive therapies alongside or following hepatotoxic anti‐TB drug regimens, especially in regions where herbal medicine is integrated into mainstream healthcare. Globally, herbal medications are gaining popularity due to their perceived safety, minimal side effects, and accessibility. In India, they are widely used in traditional medicine for managing liver complications. Numerous studies have investigated the potential of herbal or phytochemical compounds to counteract anti‐TB drug‐induced hepatotoxicity without interfering with the efficacy of drugs []. These formulations often contain bioactive phytochemicals that serve as hepatoprotective agents by inhibiting cytochrome P450 and microsomal drug‐metabolizing enzymes and also as antioxidants to reduce oxidative stress and tissue damage. References to such plant‐based hepatoprotective treatments are found in ancient indigenous medical systems and remain in practice among rural and tribal communities worldwide, including in India []. Given the well‐documented hepatotoxicity of first‐line antitubercular drugs and the promising evidence for the efficacy of certain plants, there is a critical need to explore plant‐based therapeutic alternatives. Traditional medical systems offer a rich source of hepatoprotective plants with antioxidant and enzyme‐regulating properties. This systematic review aims to evaluate the efficacy of herbal extracts in preventing anti‐TB drug‐induced liver injury (DILI) and to provide evidence‐based insights into their potential role as adjunctive therapies in TB management. 2. Methodology 2.1. Protocol Registration The review was developed according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses Protocol (PRISMA‐P) guidelines. 2.2. Exploration Approach of Primary Studies The literature search was performed using electronic bibliographic databases Scopus, PubMed, and Google Scholar. Two reviewers independently reviewed the titles and abstracts for relevant articles, excluding irrelevant ones. Discrepancies were discussed or escalated to a neutral third party for a final determination. Later, the full‐text research articles satisfying the criteria were retrieved and separately examined by the two authors to determine the final set of studies for review. A thorough search was run using acceptable keywords to retrieve all relevant articles. For example, the search words used were “TB, White Plague, Koch’s Disease, Pulmonary tuberculosis, Lung TB,” and “Medicinal herbs, Traditional herbs, Ethnobotanical plants, Herbal medicines, Plant‐based therapies, Natural remedies, Traditional Medicinal Plants” and “Liver toxicity, Hepatic toxicity, Liver damage, Hepatocellular damage, Hepatic adverse effects, Drug‐induced hepatotoxicity, Hepatotoxicity” and “Tuberculosis medications, TB antibiotics, TB drugs, Anti‐tubercular drugs, Anti‐TB medications, Anti‐Mycobacterial drugs, Anti‐TB drugs” (Supporting table no. ). All search results were imported into Rayyan QCRI software (Qatar Computing Research Institute, Hamad Bin Khalifa University, Doha, Qatar; Version 2.0) to ensure a thorough and systematic search and to document the selection process. 2.3. Inclusion and Exclusion Criteria 2.3.1. Inclusion Criteria - • Study design: Comparative experimental in vivo studies conducted between 2002 and 2024 - • Intervention: Plant extracts for hepatoprotective activity - • Comparators: (standard group—silymarin, toxic group—antitubercular medicines, and treatment group—plant extracts) - • Animal models: Studies on Wistar male or female rats and rodent models of antitubercular drug‐induced hepatotoxicity were considered. - • Dosage range: The dose range for antitubercular medicines was considered between 25 and 200 mg/kg, followed by the range for medicinal plants between 50 and 1000 mg/kg. - • Outcome measures: The studies that analyzed liver function, including aspartate aminotransferase (AST) in U/L, alanine transaminase (ALT) in U/L, alkaline phosphatase (ALP) in U/L, total bilirubin (TBil) in mg/dL, and antioxidant enzyme parameters, including GSH in mM/mg, catalase (CAT) in U/mg, and superoxide dismutase (SOD) in U/mg, were included (Table ). 2.3.2. Exclusion Criteria The criteria used to exclude studies are as follows: - •In vitro studies without in vivo validation - •Studies lacking appropriate controls - •Case reports, reviews, conference abstracts, and editorials - •Studies not reporting quantitative outcome data suitable for meta‐analysis - •Studies investigating hepatoprotection against toxins other than anti‐TB medications - •Duplicate publications or overlapping datasets 2.4. Data Extraction A data extraction form was used to extract information systematically from research publications. Full‐text articles from the databases listed above were downloaded. The retrieved data were loaded with the following titles into the Microsoft Excel Software: study ID, plant part, state/country, anti‐TB medicines, standard group, toxic group, toxic dose concentrations, number of days, and different parameters such as AST, ALT, ALP, TB, GSH, CAT, and SOD (Supporting table no. ). 3. Results 3.1. Selection of Included Studies Out of the 565 articles identified through the mentioned search databases, 327 were removed owing to duplication. After examining the titles and abstracts of 238 papers, 156 were excluded for lack of relevance. After reviewing 82 full‐text papers, 68 of them were chosen based on pre‐established inclusion and exclusion criteria [, , , –]. The screened research articles provided sufficient evidence of the effect of herbal extracts on antitubercular drug‐induced hepatotoxicity across the chosen parameters. Several studies included data on various animal models, enzyme parameters, anti‐TB medications, and doses. The entire screening process is represented using a PRISMA flowchart (Figure ). The included studies were analyzed for the effect of the plant extracts on the liver enzymes and their antioxidant properties, details of which are narrated below: AST: It is observed from the analysis of the AST levels from all selected studies that there is significant variation in hepatoprotective activities among plant extracts (Table ). Among all the plant extracts included in the studies, it is observed that the extracts from Luffa acutangula L., Cucumis trigonus Rox., and Ocimum canum Sims. showed the highest hepatoprotective activity, with > 75% reduction in AST levels compared to the toxic control group (Table ). Lawsonia inermis L., Asparagus racemosus W., Centella asiatica L., Allium sativum L., Persea americana Mill., and Telfairia occidentalis Hook., and Saccharum officinarum L. extracts show significant hepatoprotection, as indicated by a 60%–75% reduction in AST level (Table ). Moderate hepatoprotection, indicated by a 40%–60% reduction in AST level, is shown by various plants such as Annona squamosa L., Azadirachta indica L., Crocus sativus L., Leucas cephalotes R., Polygonatum cirrhifolium W., Mirabilis jalapa L., Glinus lotoides L., Ficus religiosa L., Bacopa monnieri L., Pongamia pinnata L., Telfairia occidentalis Hook., Euphorbia fusiformis B., Carica papaya L., Ensete ventricosum Welw., Sesbania grandiflora L., Amaranthus graecizans L., Citrus sinensis L., and Calotropis procera Aiton (Table ). However, it is also observed that a few of these studies showed minimal or inadequate hepatoprotection, as indicated by a lack of significant reduction in AST levels or even showed higher AST levels in comparison to those of the toxic group (Table ). Some of the plant extracts, such as Luffa acutangula L. (400 mg), Amaranthus graecizans L. (400 mg), and Allium sativum L. (300 mg), have significantly outperformed silymarin (100–200 mg) in lowering the AST levels. However, it should be noted that these results are mostly derived from standalone research studies, and the concentrations of the plant extracts used are higher than those of the standard (silymarin). Though silymarin used in these studies is a pure compound, the plant extracts are concoctions of many phytochemicals. Therefore, we predict that the aforementioned plant extracts could be a potential source of hepatoprotective bioactive molecules. ALT: It is observed from the analysis of the ALT levels from all selected studies that there is significant variation in hepatoprotective activities among plant extracts. The highest reductions in ALT levels (> 75%) were reported for extracts of Cucumis trigonus Roxb., Luffa acutangula L., Asparagus racemosus W., Ocimum sanctum L., Allium sativum L., Persea americana Mill., and Telfairia occidentalis Hook., and Glinus lotoides L., indicating strong hepatoprotective potential compared to the toxic (Table ). A significant hepatoprotective effect (60%–75% reduction) was observed with extracts from Centella asiatica L., Citrus sinensis L., Mirabilis jalapa L., Pongamia pinnata L., Saccharum officinarum L., Calotropis procera A., and Acanthospermum hispidum DC (Table ). Extracts from several other plants, including Bacopa monnieri L., Ficus benghalensis L., Monotheca buxifolia F., Garcinia kola H., Embelia tsjeriam-cottam A.DC., Allium sativum L., Ficus religiosa L., Telfairia occidentalis Hook., Amaranthus graecizans L., Cassia auriculata L., Annona squamosa L., Telfairia occidentalis Hook., Adenanthera pavonine L., Azadirachta indica L., and Hedyotis corymbosa L., demonstrated moderate hepatoprotective activity (40%–60% reduction in ALT levels) (Table ). However, it is also observed that a few of these studies showed minimal or inadequate hepatoprotection, as indicated by a lack of significant reduction in ALT levels, or even showed higher ALT levels in comparison to those of the toxic group (Supporting table no. ). ALP: It is observed from the analysis of the ALP levels from all selected studies that there is significant variation in hepatoprotective activities among plant extracts. The highest reduction (> 75%) in ALP levels was reported for the extract from Luffa acutangula L., demonstrating pronounced hepatoprotective potential. A significant protective effect (60%–75% reduction) was observed for extracts from Ocimum sanctum L., Allium sativum L., Asparagus racemosus W., Lawsonia inermis L., Persea americana Mill., and Telfairia occidentalis Hook., Mucuna pruriens L., and Amaranthus graecizans L. (Table ). Several other extracts from other plant species, Allium sativum L., Curcuma longa L. (Haridra Ghrit), Glinus lotoides L., Garcinia kola H., Pongamia pinnata L., Mirabilis jalapa L., Crocus sativus L., Bacopa monnieri L., Moringa oleifera L., Calotropis procera A., Punica granatum L., Vitex negundo L., Azadirachta indica L., Cucumis trigonus Roxb., Centella asiatica L., Carica papaya L., and Leucas cephalotes R., demonstrated moderate hepatoprotective activity (40%–60% reduction in ALP levels), including Table . In contrast, some studies reported ALP reductions below 40%, indicating limited hepatoprotective efficacy. Overall, most plant extracts demonstrated moderate protective effects comparable to the reference hepatoprotective agent silymarin (Supporting table no. ). In addition to the liver enzymes, the study also examined antioxidant markers like TBil, GSH, CAT, and SOD. TBil: It is a measure of liver dysfunction that was lowered considerably upon treatment with most plant extracts. TBil showed substantial improvement following treatment with several plant extracts across the included studies. Extracts from Euphorbia fusiformis B., Cucumis trigonus Roxb., Lawsonia inermis L., and Mirabilis jalapa L. showed the greatest significant reductions (> 75%) in TBil levels compared to the toxic control group (Table ). Extracts from Embelia tsjeriam-cottam A.DC., Pongamia pinnata L., Garcinia kola H., Acanthospermum hispidum DC., Sesbania grandiflora L., Curcuma longa L. (Haridra Ghrit), and Bacopa monnieri L. showed a significant decrease in bilirubin levels (60%–75%), indicating hepatoprotective potential (Table ). Additionally, moderate reductions (40%–60%) were observed for extracts from Abelmoschus ficulneus L., Amaranthus graecizans L., Hedyotis corymbosa L., Leucas cephalotes R., Telfairia occidentalis Hook., Carica papaya L., Moringa oleifera L., Allium sativum L., Ficus benghalensis L., and Monotheca buxifolia F. when compared to the toxic group (Table ). Collectively, these results show that, while certain plant extracts significantly reduced TBil levels, the majority showed moderate hepatoprotective effects compared to silymarin (Supporting table no. ). GSH: GSH is a major intracellular antioxidant and is crucial in protecting the liver from oxidative stress. GSH levels provide insight into the antioxidant restorative potential of the plant extracts tested against the toxic group. Several extracts showed a significant increase in intracellular GSH levels, indicating effective oxidative stress reduction. Garcinia kola H., Leucas cephalotes R., Trapa natans Roxb., Ficus benghalensis L., Abelmoschus ficulneus L., Luffa acutangula L., and Cissus quadrangularis L. extracts exhibited the highest rate of restoration (> 75%), indicating a considerable improvement of cellular antioxidant defense (Table ). Mucuna pruriens and Embelia tsjeriam-cottam A.DC. showed an increase in GSH levels (60%–75%), indicating important antioxidative action. Additionally, Pongamia pinnata L., Centella asiatica L., Mirabilis jalapa L., Nyctanthes arbor-tristis L., Cucumis trigonus Roxb., and Alpinia officinarum H. all showed moderate GSH restoration (40%–60%) (Table ). Overall, while certain plant extracts significantly increased GSH levels, some showed moderate recovery of antioxidant capacity, which was generally comparable to the effect of the reference hepatoprotective drug silymarin (Supporting table no. ). CAT: CAT activity demonstrated a clear enhancement in several plant‐treated groups under toxic conditions, reflecting improved antioxidant defense mechanisms. The most pronounced elevation in CAT activity (> 75%) was observed with Maytenus royleanus W., Annona squamosa L., Embelia tsjeriam-cottam A.DC., Luffa acutangula L., Abelmoschus ficulneus L., and Trapa natans Roxb., indicating strong restoration of endogenous antioxidant capacity (Table ). A considerable increase (60%–75%) in CAT activity was reported for Alpinia officinarum H., Garcinia kola H., and Cucumis trigonus L., suggesting notable antioxidative effects (Table ). In addition, moderate enhancement (40%–60%) was documented for Mirabilis jalapa L. and Cnidoscolus chayamansa McVaugh (Table ). Overall, these outcomes suggest that most plant extracts increased the CAT levels significantly, while a few plant extracts provided mild antioxidant restoration that was broadly comparable to the reference hepatoprotective drug silymarin (Supporting table no. ). SOD: SOD activity recovered significantly in several plant‐treated groups across the included experiments, indicating an increase in enzymatic antioxidant defense. The most pronounced enhancement (> 75%) in SOD activity was observed in Alpinia officinarum H., Cassia auriculata L., Azadirachta indica L., Centella asiatica L., Garcinia kola H., Punica granatum L., Mucuna pruriens L., Embelia tsjeriam-cottam A.DC., and Cucumis trigonus Roxb., indicating strong restoration of antioxidant enzyme activity (Table ). A substantial increase (60%–70%) was reported for Cissus quadrangularis L. and Leucas cephalotes R., suggesting considerable antioxidative potential (Table ). Additionally, moderate increases in SOD activity (40%–60%) were observed in Maytenus royleanus W., Adenanthera pavonina L., Ocimum canum Sims., Sesbania grandiflora L., Nyctanthes arbor-tristis L., Trapa natans H., and Abelmoschus ficulneus L., indicating partial antioxidant enzyme activity restoration under toxic conditions (Table ). Cnidoscolus chayamansa McVaugh, on the other hand, had a rather minor impact on SOD modulation. Overall, the majority of the evaluated plant extracts showed improvements in SOD levels that were generally comparable to the antioxidant response observed with the standard hepatoprotective agent silymarin, supporting their potential role in mitigating oxidative stress‐associated hepatic injury (Supporting table no. ). 3.2. Quality Assessment Quality assessments were performed using SYRCLE’s scale, which ensures that the included animal studies are reliable, unbiased, and well‐designed (Supporting table no. ). Most of the key methodological details, such as random sequence generation, allocation concealment, and blinding, were frequently unclear or not reported. This indicates a moderate risk of bias and highlights the need for improved transparency in study design. Overall, while the data are generally reliable, future studies should enhance methodological reporting to strengthen the validity of their findings. 4. Discussion In this systematic review, preclinical data were employed to evaluate the hepatoprotective activity of medicinal plants against liver injury caused by antitubercular drugs, commonly known as DILI. Among the selected 68 studies on medicinal plants, some exhibited better hepatoprotective activity upon biochemical and antioxidant marker‐based assessments. Notably, Luffa acutangula L., Lawsonia inermis L., and Cucumis trigonus L. consistently ranked the highest in hepatoprotective activity by exhibiting reduction in the AST, ALT, ALP, and TBil profiles (Table ). Extracts from plants such as Garcinia kola H., Trapa natans L., Abelmoschus ficulneus L., and Embelia tsjeriam-cottam A.DC. exhibited enhanced antioxidant activity by increasing the GSH, CAT, and SOD levels (Table ). Interestingly, Luffa acutangula L. and Cucumis trigonus L. were helpful in the reduction of the AST, ALT, ALP, and TBil alongside their antioxidant activity. A few plant extracts showed moderate hepatoprotective activity, which may vary due to various reasons such as differences in phytochemical content, extraction methods, experimental models, and dosages. The hepatoprotective activity of these promising plant species may be attributed to various phytochemicals such as flavonoids, phenolic derivatives, terpenoids, and sulfur‐containing compounds, which are known to affect oxidative stress, inflammatory pathways, and detoxification processes in the liver []. Oxidative stress is considered one of the major mechanisms underlying anti‐TB drug‐induced hepatotoxicity. First‐line anti‐TB drugs generate ROS and reactive metabolites that promote lipid peroxidation, mitochondrial dysfunction, depletion of endogenous antioxidant defenses, and hepatocellular injury. Many plants included in the present review demonstrated restoration of antioxidant enzymes such as SOD, CAT, and GSH, along with a reduction in lipid peroxidation markers, suggesting that modulation of oxidative stress pathways may be a key mechanism responsible for their hepatoprotective activity. In addition, phytochemicals such as flavonoids and phenolic compounds are known to exert anti‐inflammatory and free radical scavenging effects that may further contribute to hepatocellular protection [, , –]. Several plant extracts outperformed silymarin (standard) across key hepatotoxicity markers in preclinical studies, as shown in Table . However, these findings largely stem from single studies, with extract doses often exceeding those of silymarin, a pure compound, while the extracts represent complex mixtures of phytochemicals. Thus, the above‐mentioned extracts warrant further investigation as promising sources of hepatoprotective bioactive molecules. A recent systematic review and network meta‐analysis that included 14 randomized controlled trials involving 3423 human patients demonstrated that a combination of Curcuma longa (turmeric) and Tinospora cordifolia, as well as N‐acetylcysteine (NAC), significantly reduced the incidence of anti‐TB DILI compared to the placebo; Additionally, polyherbal formulations were found to significantly lower serum ALP and TBil levels []. Several in vivo studies have highlighted the hepatoprotective properties of individual plant species. For instance, Silybum marianum (milk thistle) has shown significant protective effects primarily through its active compound, silymarin, which stabilizes hepatic cell membranes, reduces lipid peroxidation, and promotes liver regeneration []. Polyherbal preparations such as Liv52 are also commonly used hepatoprotective drugs that exert their activity against toxin‐induced liver damage via antioxidant and membrane‐stabilizing actions [, ]. Despite the growing popularity of herbal hepatoprotective supplements, research articles that used several widely recognized medicinal plants, such as Phyllanthus niruri and Andrographis paniculata, were not included in the present analysis due to the predefined inclusion criteria and the selected publication period (2002–2024) []. However, both of these plants are well known for their hepatoprotective potential and have been explored for their ability to prevent antitubercular DILI []. The study showed the hepatoprotective potential of Phyllanthus niruri and Andrographis paniculata in INH‐ and RIF‐induced hepatotoxicity in rats and demonstrated that extracts from both plants significantly reduced elevated liver enzyme levels and increased antioxidant defense mechanisms, protecting the liver from damage caused by antitubercular drugs []. This potential of Phyllanthus niruri and Andrographis paniculata was largely attributed to their antioxidant and anti‐inflammatory properties, which are known to mitigate oxidative stress and liver injury caused by antitubercular drugs []. The current systematic review has several limitations that should be acknowledged. Although this review consolidates the available preclinical evidence on plant extracts for managing anti‐TB DILI, most results are supported by only a single experimental study, limiting the strength of the conclusions and highlighting the need for independent replication. Methodological inconsistencies further challenge the internal validity of the findings. One notable observation is the inconsistency in outcome parameters across the selected studies, which exhibit substantial variability. Each study employed different experimental conditions, including anti‐TB drug concentrations, durations of animal experimentation, assay kits, silymarin as the standard at different concentrations, extraction solvents for plant extracts, and the final concentrations of the plant extracts. Moreover, the absence of baseline values for control animals (untreated with anti‐TB drugs) further compromises the reliability of these findings. However, it should also be noted that the percentage restoration may overestimate hepatoprotective efficacy in studies with extremely elevated toxic controls. Moreover, the translational gap between preclinical models and clinical practice remains a major barrier, restricting the direct applicability of these findings to human health interventions. Another important consideration is the variability among the included experimental models. Differences in animal species and strains, anti‐TB drug regimens, treatment duration, extraction procedures, dosage protocols, and outcome assessment methods may contribute to heterogeneity across studies and affect comparability of findings. Furthermore, preclinical animal models provide important mechanistic insights. The translation of these findings into clinical application remains challenging due to limited clinical studies, a lack of standardized herbal formulations, and insufficient long‐term safety evaluations. 4.1. Clinical and Research Implications This systematic review evaluates preclinical evidence on medicinal plants’ hepatoprotective effects against anti‐TB DILI, identifying standout performers like Luffa acutangula L., Lawsonia inermis L., and Cucumis trigonus L. for reducing AST, ALT, ALP, and TBil, alongside others (e.g., Trapa natans L., Abelmoschus ficulneus L.), boosting GSH, CAT, and SOD beyond silymarin. These benefits likely stem from phytochemicals such as flavonoids and terpenoids targeting oxidative stress, with clinical parallels in Curcuma longa/Tinospora cordifolia and NAC trials []. The systematic identification of effective plant‐based interventions provides a basis for prioritizing further investigations into their mechanisms of action and potential integration with conventional anti‐TB therapy. Such research may facilitate the development of adjunctive therapies in the future that mitigate drug‐induced hepatotoxicity while preserving therapeutic efficacy. 5. Conclusions The current systematic review provides a comprehensive synthesis of preclinical evidence regarding the hepatoprotective potential of medicinal plants against antitubercular DILI. Medicinal plant extracts, particularly Luffa acutangula L., Lawsonia inermis L., and Cucumis trigonus L., demonstrated significant hepatoprotective activity in experimental models, showing improvements in hepatic biomarkers, antioxidant parameters, and histopathological outcomes comparable to or exceeding those of standard hepatoprotective agents such as silymarin. These protective effects are largely attributed to the presence of bioactive phytochemicals, including flavonoids, phenolics, terpenoids, and sulfur compounds, which may exert antioxidant, anti‐inflammatory, and cytoprotective effects. The findings of this review support the growing therapeutic potential of plant‐based adjunctive interventions for the management of antitubercular drug‐induced hepatotoxicity. However, further studies are required to establish their translational applicability. Future research should focus on detailed mechanistic investigations, standardization of plant extracts, optimization of dosage regimens, long‐term toxicity evaluation, and well‐designed preclinical and clinical studies to validate safety and efficacy. Such advances may facilitate the development of effective adjunct therapies capable of reducing hepatotoxicity, improving treatment adherence, and enhancing clinical outcomes in TB management. Disclosure All authors reviewed and approved the final manuscript. Ravedar, Surthi M. , Akula, Kranthi Kiran , Karun, Kalesh M. , Felix, Flemin , Zaman, Kamran , Bhat, Jyothi , Roy, Subarna , Effect of Herbal Extracts on Antituberculosis Drug‐Induced Hepatotoxicity: A Systematic Review, Journal of Toxicology, 2026, 6698835, 18 pages, 2026. 10.1155/jt/6698835 Contributor Information Jyothi Bhat, Email: bhatdr@gmail.com. Lissinda H. Du Plessis, Email: lissinda.duplessis@nwu.ac.za